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Introduction: Thrombosis remains the most common preventable cause of mortality in cancer 
patients receiving chemotherapy. Whilst the prophylaxis and treatment of this condition is well 
understood, the patient experience and subsequent behavioral factors are not.
Methods: Patients receiving treatment for cancer-associated thrombosis (CAT) were 
interviewed about their experiences of CAT within the context of their cancer journey. Twenty 
interviews were transcribed and analyzed using framework analysis.
Results: Chemotherapy patients were well informed about the risks of febrile neutropenia, 
how to recognize it, and when to seek medical attention. However, they had limited knowledge 
about CAT and received no information about the condition. Red flag symptoms sugges-
tive of CAT were attributed to chemotherapy or the underlying cancer, resulting in delayed 
presentation to hospital, and diagnosis. The CAT journey was considered a distressing one, with 
limited support or information, in complete juxtaposition with the treatment they received for 
their cancer. Patients felt there was little ownership for the management of CAT, which further 
added to their distress.
Conclusion: CAT is a common occurrence and patients view their experiences of it within 
the context of their overall cancer journey. However, patients receive little information to help 
recognize CAT and access timely treatment on the development of symptoms. Whilst other cancer 
complications have clear treatment pathways, thrombosis does not appear to have been afforded 
the same priority. A proactive approach to increase patient awareness, coupled with established 
CAT pathways is likely to reduce mortality, morbidity, and long-term psychological distress.
Keywords: venous thromboembolism, qualitative, patient journey, low-molecular-weight 
heparin, patient experience
Introduction
Venous thromboembolism (VTE), comprising of deep vein thrombosis (DVT) 
and pulmonary embolus (PE) is a common phenomenon, which occurs in one in 
1,000 patients and annually affects 6.5 million people worldwide.1,2 The rate is higher 
in the cancer population, accounting for 18% of all VTE cases.3 Up to 20% of patients 
with malignancy will develop cancer-associated thrombosis (CAT) during the course 
of their disease.4 Of these, over 50% will occur in the first 3 months of diagnosis, thus 
complicating cancer treatments, as well as conferring additional symptom burden. 
In addition to acute and long-term morbidity, CAT remains the number one cause 
of death during chemotherapy and the most common cause of all cancer deaths sec-
ond only to disease progression.5,6 The challenges of managing CAT are also well 
recognized; cancer patients are at greater risk of both recurrent VTE and bleeding 
complications compared to those without malignancy.6–8
Clinical guidelines recommend that the first-line treatment of CAT require 3–6 months 
anticoagulation with weight-adjusted low-molecular-weight heparin (LMWH).9–11 Despite 
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the high-quality evidence informing treatment options, there is 
limited data on how CAT and its treatment impacts on the patient 
experience or quality of life, with the majority of research focus-
ing on VTE in the non-cancer setting.12–17 This is of particular 
relevance, since experiences of CAT may have an additional 
impact on the preexisting cancer journey, and ultimately, the can-
cer outcome. Qualitative research in the non-cancer population 
has identified that VTE has a significant negative psychological 
impact, including symptoms suggestive of posttraumatic stress 
disorder being reported.18 Specific to CAT, three qualitative 
studies have been published; two studied the acceptability of 
long-term LMWH in its treatment and one explored the expe-
riences of patients receiving cancer treatment who developed 
a VTE.19–21 Emerging data from these studies suggested that 
patients felt that there were several areas of unmet need within 
the diagnosis and treatment of CAT.21 We therefore undertook a 
qualitative study to explore the wider patient experience of living 
with CAT. Specifically, the study aims were to explore:
• the CAT journey through the lived patient experience;
• the meaning of CAT to patients within the context of the 
cancer journey;
• the impact of the treatment for CAT;
• the emotional impact of CAT;
• unmet areas of need within the CAT journey.
Methods
Data collection
Ethical approval was granted by the National Research Eth-
ics Service (NRES) Committee South Central – Oxford B 
(reference 13/SC/041). Patients attending a dedicated CAT 
clinic, within a regional cancer center and district general 
hospital, were sequentially screened for inclusion into the 
study. The lead author (SN), who was also a clinician man-
aging patients with CAT, undertook screening. All eligible 
patients were invited to participate. Where patients attended 
with their partner or next of kin, they were also given the 
opportunity to be interviewed.
Inclusion criteria included:
• histologically confirmed cancer;
• receiving LMWH for a proven new VTE (DVT or PE) 
and having received such treatment for at least two con-
secutive months;
• able to consent and participate in a 40-minute interview.
Exclusion criteria included:
• non-melanoma skin cancers;
• Patients whose physical level of functioning meant that 
they were unable to converse for up to 40 minutes without 
fatigue.
All participants provided written consent, which was 
taken by the researcher at the patients’ homes prior to the 
interview commencing. Semi-structured interviews were car-
ried out over a 5-month period between November 2013 and 
March 2014 by an experienced qualitative researcher (HP). 
Interviews were guided by a prompt list to ensure that the 
same issues were discussed at each interview.
The researcher, who was from a nursing background, 
had no prior relationship with participants or declared clini-
cal interest in CAT management. Data were elicited on the 
following:
• their experience of being diagnosed with CAT;
• the physical and emotional impact of CAT and its 
treatment;
• how their care could be improved.
To facilitate this, questions were open-ended, with the use 
of prompts to probe further into issues that arose as significant 
or meaningful to the participant. Interviews were digitally 
recorded and transcribed verbatim. Field notes were also 
taken. Interviews took approximately 40 minutes each. No 
repeat interviews were necessary; neither did any aspects of 
transcripts require additional checking with participants.
Analysis
Transcripts were typed into a Word document and uploaded 
to NVivo 10 computer software for data management.22 Data 
analysis was undertaken using a methodology increasingly 
used in health care research, framework analysis (FA). This 
was considered the most appropriate analytic method to 
enable a deductive approach toward creating an analytic 
framework based on the interview schedule, whilst also 
allowing room for inductive observations.23 Analysis was 
undertaken using Ritchie and Spencer’s five interconnected 
stages inherent in FA:
1. Familiarization with data: listening to recordings, 
re-reading field notes and transcripts, and listing key 
ideas and recurrent themes.
2. Identifying a thematic framework: reviewing the data and 
identifying key issues, concepts, and themes to develop 
an index of themes informed by the research aims and 
the issues raised by the respondents themselves.
3. Indexing the data: systematically applying the thematic 
framework or index to each of the transcripts. This 
framework may be adjusted as it is applied to subsequent 
transcripts.
4. Charting: lifting the data from the transcripts and rear-
ranging it according to its thematic reference. At this 
stage, a chart can be drawn up.
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5. Mapping and interpretation: comparing and contrasting 
themes, searching for a structure, and using diagrams and 
tables to explore relationships.
Results
Participant characteristics
Of 25 eligible patients invited to participate, 20 consented 
(ten males, ten female). Patient characteristics are sum-
marized in Table 1. Patients were aged between 53 and 
81 years old (mean: 68 years) representing seven different 
primary cancers including lung (n=4), colorectal (n=4), breast 
(n=4), prostate (n=2), and ovarian (n=2). Participants had 
been receiving LMWH for between 2 and 20 months (mean: 
8 months, median: 6 months).
Principal findings
Analysis of the data identified three major themes, illustrat-
ing key phases in the CAT journey, namely: life before 
CAT, diagnosis and treatment of CAT, and living with CAT. 
These, along with associated subthemes, are outlined in 
Figure 1 and discussed below with accompanying interview 
excerpts. Excerpts of interviews were selected on the basis 
of two criteria. Firstly, they illustrate the issue being dis-
cussed and secondly, an attempt was made to use a spread 
of participants rather than rely on a few individuals. Figure 2 
further illustrates participants’ subjective account of the CAT 
journey, identifying points at which key interventions were made 
during the diagnosis, treatment, and ongoing management.
life before cAT
In non-cancer patients, VTE usually presents subsequent to 
a short period of medical illness or surgery in patients who 
normally enjoy good health. However, CAT most commonly 
occurs within the first 3 months of a cancer journey and is as 
such experienced within the context of an already diagnosed 
life-threatening condition.
lack of knowledge of VTe in the context of cancer
Whilst most participants had heard of VTE, none had been 
aware of an association with cancer. Long-haul flights were 
most commonly cited as a risk factor:
[…] cos I do long-haul flights […] I do all the things, the 
long socks, I walk up and down the plane, you know so I’m 
aware of the seriousness of a blood clot. [VCC02]
[…] they’re in the news quite a bit with people drop-
ping dead when getting off an aeroplane and things like 
that. [VCC12]
Table 1 characteristics of study participants including age, sex, cancer details, VTe details, and length of time on treatment
Code Age  
(years)
Sex  
M/F
Cancer diagnosis VTE details Injection given  
by self or carer
LMWH Rx 
duration
Vcc01 53 M Metastatic lung Pe (sym) Wife 8 months
Vcc02 64 F Metastatic breast Pe (sym) self 20 months
Vcc03 61 F Metastatic lung DVT (sym) self 5 months
Vcc04 74 M colorectal Pe (inc)
DVT (sym)
self 4 months
Vcc05 64 F Metastatic breast Pe (sym) self 20 months
Vcc06 72 M Mesothelioma Pe (sym)
DVT (sym)
self 10 months
Vcc07 73 F Metastatic colorectal Pe (sym) self 7 months
Vcc08 80 F Breast DVT (sym) self 2 months
Vcc09 66 M lung DVT (sym) sister, and then self 7 months
Vcc10 81 F Metastatic ovarian Pe (sym) self 6 months
Vcc11 74 M Metastatic prostate Pe (sym) self 14 months
Vcc12 69 M Pancreas Pe (sym)
DVT (sym)
self 3 months
Vcc13 57 M colorectal Pe (sym) Wife 4 months
Vcc14 58 F Metastatic ovarian DVT (sym) Daughter 9 months
rg01 77 M Metastatic unknown primary DVT (sym) self 5 months
rg02 57 F Ovarian Pe (sym) husband 6 months
rg03 69 M Metastatic colorectal Pe (inc) self 6 months
rg04 73 F Metastatic colorectal DVT (sym) husband 8 months
rg05 80 M Metastatic prostate DVT (sym) self 4 months
rg06 67 F Breast DVT (sym) self 6 months
Abbreviations: DVT, deep vein thrombosis; inc, incidental; F, female; lMWh, low-molecular-weight heparin; M, male; Pe, pulmonary embolus; rx, prescription; 
sym, symptomatic; VTe, venous thromboembolism.
Patient Preference and Adherence 2015:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
340
noble et al
Figure 1 Major themes and associated subthemes.
Abbreviations: cAT, cancer-associated thrombosis; VTe, venous thromboembolism.
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Specifically, none knew of the association between VTE 
and cancer:
[…] that it could happen yeah, cos you’re half expecting it 
then, in a way, but er, and I have learnt that more people die 
from clots in the lungs and everything else after cancer than 
they do from cancer, and you’re never told that, so I thought 
well it is a major point, you know these clots. [VCC07]
Patients unaware of risks of thrombosis 
or symptoms to look out for
Patients reported little prior knowledge of the association 
between thrombosis with cancer or warning signs that they 
had developed VTE. Whilst patients receiving chemotherapy 
were advised on what they should do if they developed signs 
and symptoms of neutropenic sepsis, none recalled being 
told of the increased risk of VTE and associated symptoms, 
which would necessitate seeking medical attention.
[…] but they don’t tell you you’re gonna get clots after chemo, 
that’s the one thing they haven’t, they never said but we, we 
just put it down to, it’s just my breathing […] just that one 
item of information that we weren’t aware of. [VCC07]
Consequently, when patients developed symptoms sug-
gestive of DVT or PE, several attributed them to the chemo-
therapy and did not consider thrombosis as a cause.
[…] but um this time again first set of chemo, she felt ter-
rible and the thing is, when we went back to hospital really 
desperate, the only problem we thought was that it was the 
chemotherapy that was causing it. [RG02]
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Figure 2 illustration of cAT journey with experiences at respective phases.
Abbreviations: cAT, cancer-associated thrombosis; lMWh, low-molecular-weight heparin; Pe, pulmonary embolus; VTe, venous thromboembolism.
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[…] but I didn’t realize that that was what causing it 
like, obviously a clot like you know, I didn’t have any pain 
or anything, I just thought I was getting short of breath 
anyway like, do you know what I mean, because of the 
chemo and everything. [VCC04]
Some patients also attributed symptoms of VTE to the 
worsening of preexisting comorbidities.
If I didn’t have the mild asthma, I would have picked it, 
would pick up quicker […] But I suppose somebody that 
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didn’t have asthma in the same thing would pick up on that 
quicker maybe and would have gone to the GP and maybe 
they would have taken a different route […] cause maybe 
they [the GPs] were a little bit side-lined by the asthma as 
well. [RG03]
limited awareness amongst health professionals
The limited awareness of CAT was not restricted to patients. 
Several patients perceived a lack of knowledge amongst health 
care professionals. When patients presented with symptoms 
attributable to DVT or PE, alternative diagnoses were often 
considered first. Some perceived that this led to a delay in 
definitive diagnosis. One patient presenting with unilateral leg 
swelling was treated for several months with escalating doses 
of diuretics even when this did not lead to improvement.
It just got bigger and bigger and bigger, over months really 
[…] then they doubled them (diuretics), and then they 
trebled them. [RG05]
Patients with new or increased dyspnea with chest pain 
were often treated first with antibiotics for a presumed chest 
infection.
I went to the doctor and she listened and whatever and said 
it was probably pleurisy. [VCC12]
They said it was probably pleurisy, gave me antibiotics 
[…] it was a pain I’d never had before. [VCC11]
Diagnosis and treatment of cAT
Participants described two distinct pathways leading to the 
diagnosis of CAT;
1) Diagnosis of incidental thrombosis
A small proportion of patients had their CAT diagnosed 
as an incidental finding on a scan undertaken for another 
purpose (usually to stage the cancer). Patients were 
usually asymptomatic for thrombosis and not expecting 
an additional diagnosis to their cancer.
2) Diagnosis of symptomatic VTE
The majority of participants reported presenting with 
distressing symptoms that prompted investigation for 
VTE. These included dyspnea, chest pain and hemoptysis 
(for PE) and leg swelling, pain, and erythema (for DVT). 
These patients were expecting an explanation for their 
unpleasant symptoms.
initial reaction of shock
Previous research in non-cancer patients has identified 
the feeling of shock at the diagnosis of VTE.18 This was 
also experienced by those diagnosed during their cancer 
journey.
[…] like everything else, it’s a shock at first. [RG05]
Distress appeared to be augmented in cancer patients as 
they viewed their VTE in the context of their overall cancer 
journey. As such, they perceived the CAT to be a compli-
cation of the cancer, which consequently inferred a worse 
overall prognosis.
[…] and you think ah crumbs, what’s next, you know, 
what’s going to happen next? [RG06]
I think we both thought oh God, what else? […] what 
else is going to happen? [VCC11]
[…] having the cancer and then the thrombosis on top 
of it, erm, not knowing how bad it was when I went in,  
I know I was in terrific pain with my chest and that erm, it 
was frightening to be honest. [VCC01]
little information
Patients reported the diagnostic process to be rushed, with little 
explanation as to what was happening. When the diagnosis of 
CAT was made, patients described being started on LMWH 
and discharged quickly with limited explanation or support.
Nobody really explained, […] ‘coz they need the bed, you 
know. So you don’t feel as though erm, you know, I think 
if it was a little bit more relaxed er, they probably would’ve 
got somebody you know, from a department to come and 
explain it more. [VCC05]
[…] in the beginning, it’s just in and out sort of thing 
innit, take this, take that, don’t get a lot of information. 
[RG05]
When faced with limited information, patients would 
seek answers from the Internet, thereby learning of their 
potentially fatal condition without the necessary support or 
answers to questions they may have.
[…] it’s only when you start reading up about it, you sort of 
realize just how serious erm, you know, sort of blood clots are 
[...] I was very lucky that you know, it was a fatal, you know 
attack, so er which is a little bit erm, scary. [VCC05]
Participants identified a desire for information about their 
condition. They did not require extensive details; rather, an 
overview of the condition, a treatment plan, and indicator 
of prognosis.
I don’t need, you know graphic details and chemical things. 
As long as they tell me, you know, they think that’s what 
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caused it. That’s the treatment we’re going to give you and 
it should sort it out and this is what you need to look out 
for in the future like, you know. [VCC07]
living with cAT
getting on with life
Subsequent to the initial shock of VTE diagnosis and treat-
ment initiation, participants described ‘getting on with life’ 
and settling back into their cancer journey. Over time, any 
distress attributable to CAT became less pronounced and 
even daily reminders such as the administration of LMWH 
became a routine part of daily life.
You want to try to recover and get back to some sort of um, 
you know, some sort of normality. [RG06]
Because I do it as soon as I get up and then if I’ve got to 
go anywhere it’s all done. Done and dusted. [VCC02]
I mean I just treat it as one illness to be honest [...] 
because you know, you’ve got it at the same time and the 
one was caused by the other. [RG03]
ritualization
Many patients had their LMWH initially administered by 
the district nurse, who in time trained them to self-inject. 
Self-injecting gave patients greater freedom since they did 
not have to wait at home each day for the nurse to call; 
furthermore, they were able to get the injection ‘over and 
done with’ so they could get on with their day. As such, 
the daily injection appeared to cause minimal distress or 
inconvenience.
[…] they give me the option of doing ‘em myself, that’s 
when I decided to do ‘em myself. And now I do ‘em myself, 
I do ‘em, you know, it’s to suit me. So I do ‘em in the morn-
ing. And the day’s my own then like, do you know what  
I mean like? [VCC05]
Many participants described the development of systems 
and rituals around their daily LMWH injection.
[…] is a ritual now. [VCC10]
They described the development of specific personalized 
routines, which they would strictly adhere to.
Right we sit here and I say I’ve got to have me jab.  
I go in the bedroom […] shut the door, ‘coz I got to pull 
this up, pull that down. It’s only a little thing like that. 
[VCC01]
I do it on the toilet normally, on the toilet seat. You’ve 
gotta wash the tummy first of all, get the circulation going 
right, and then you dry it, you wash your own hands then. 
[VCC08]
The development of rituals increased compliance with 
medicines but more importantly empowered patients to 
regain control over their life and not remain in the house 
waiting for a district nurse visit.
I do ‘em, you know, it’s to suit me. So I do ‘em in the morn-
ing. And the day’s my own then like, do you know what  
I mean like? [VCC05]
Discussion
The PELICAN study is the first qualitative study to explore 
the CAT journey through the patients’ lived experience and 
within the context of their ongoing cancer journey. It has 
identified three stages in the journey, namely: life before 
CAT, initial diagnosis and treatment of CAT, and living 
with CAT. Each stage is associated with specific patient 
needs, with respect to clinical intervention and process, 
information, training, and psychological support. These are 
discussed below.
life before cAT
As identified in previous studies, patients have limited 
awareness about the risks of VTE beyond that associated 
with long-haul flights. Whilst PELICAN, similarly, identi-
fied limited patient knowledge about the risk of VTE, it also 
suggested this lack of awareness may delay the diagnosis and 
subsequent treatment of CAT. It is commonplace for che-
motherapy patients to be advised of the signs and symptoms 
of neutropenic sepsis and to be given clear instructions of 
what to do in such an event.20 Since CAT is the most com-
mon cause of chemotherapy-related mortality, it would seem 
appropriate to afford similar emphasis on CAT awareness 
as is seen with neutropenic sepsis.5 In addition to earlier 
recognition and treatment of CAT, the knowledge that VTE 
is an anticipated consequence of chemotherapy may result 
in lower distress levels at diagnosis.
Diagnosis and treatment of cAT
The emotional impact of a diagnosis of cancer is well recog-
nized and an emphasis is placed on training for skills required 
to break bad news, offer emotional support, and provide nec-
essary information. A key worker, usually a specialist nurse, 
is often standard, allowing patients and families access to a 
named professional to navigate them though the sometimes 
complex diagnostic and therapeutic journey. Informing a 
patient of a diagnosis of CAT is, to all intents and purposes, 
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breaking further bad news, and yet patients receive insuf-
ficient information and support when CAT is diagnosed.
A diagnosis of CAT does not solely bring an increased 
medical burden on the patient; it should also alert health care 
professionals to additional support and information require-
ments additional to those of the cancer alone. Failure to rec-
ognize and address these needs may lead to increased distress, 
misunderstanding, and poor compliance with treatment.
living with cAT
The treatment of CAT brings with it symptomatic relief, 
reassuring patients that their condition is improving. This 
reduces distress and allows patients, over time, to get back 
to ‘some sort of normality’; normality now being their ongo-
ing cancer journey. Likewise, the initial concerns regarding 
injecting LMWH appear to quickly abate as patients develop a 
ritualistic approach to daily injections. Previous research sug-
gested reminders of the thrombotic episode event may increase 
distress and contribute to the development of chronic psy-
chological disorders such as posttraumatic stress disorder.18 
In this study, this was not the case, and it is possible that by 
developing rituals around injections normalized a procedure 
that would otherwise have served as a reminder of a distressing 
event. These results need to be considered in the context of the 
study’s strengths and limitations. The participants comprise a 
representative sample of cancer patients with thrombosis and 
cover a breadth of cancer primaries. As such, the results are 
likely to be similar to the larger CAT population. This asser-
tion is strengthened by the fact that this was a large patient 
sample with strong congruence between responses.
Whilst participants were recruited from two settings: a 
regional cancer center and district general hospital, they were 
all managed as part of a dedicated service, specializing in the 
management of CAT. Arguably, the unmet patient needs, as 
described earlier, may be greater in a more generalist service, 
and as such, these results could underestimate the challenges 
of managing CAT. In particular, the patients in this study 
had a clear lead clinician responsible for the management of 
the CAT, ie, decision making regarding length of treatment, 
dosages, and ensuring that an anticoagulant was prescribed. 
Previous research has identified lack of clinical ownership to 
be a problem and it is likely that this could contribute further 
to poor patient experience and distress.21
Many of the patient experiences outlined in this study are 
likely to be applicable to the CAT population as a whole and 
will further inform our approaches to managing the challenges 
of primary thromboprophylaxis in medical and surgical cancer 
patients.24 However, it must be acknowledged that experiences 
will also be influenced by cultural diversity and variations in 
the provision of health care systems across different popula-
tions. As such, lessons from this study cannot be considered 
a panacea of CAT patient experiences across the globe. Con-
sequently, a wider multinational study is underway across a 
breadth of countries in order to gain a global understanding 
of the experiences of patients living with CAT.
Conclusion
The diagnosis of CAT is a physically and emotionally dis-
tressing phenomenon, frequently experienced in the context 
of the major life event of a recent cancer diagnosis and ongo-
ing cancer treatment. It is a diagnosis that they have little 
knowledge or warning of and often receive inadequate sup-
port or information at the time of diagnosis. Simple changes 
to the management of CAT are likely to lead to significant 
improvements in the physical and psychological outcomes 
of the CAT. Increased awareness of the risks of CAT, how 
to recognize them, and targeted support during the diagnostic 
process are the first priorities for improving the management 
of this common oncological complication. In summary, 
this paper highlights that regardless of the strong evidence 
supporting the diagnosis and treatment of CAT, without an 
insight into the patient experience of it, we are unlikely to 
deliver optimal patient-centric treatment.
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